November 1, 2009
By:Kenneth A. Getz
Economic factors and sponsor practices will dramatically alter the investigative site landscape.
 |
July 1, 2009
By:Kenneth A. Getz
The public would be best served if both recognize their own questionable practices.
|
May 1, 2009
By:Kenneth A. Getz
Out of necessity, providers may finally become valued strategic partners.
|
March 1, 2009
By:Kenneth A. Getz
Drug development, largely immune to past economic downturns, now faces a different climate.
|
January 1, 2009
By:Kenneth A. Getz
A look at the vague but time consuming requirements imposed on sites and efforts to ease the burden.
|
November 1, 2008
By:Kenneth A. Getz
Teaching informed risk benefit assessment is a first step in restoring public trust.
|
September 1, 2008
By:Kenneth A. Getz
The public considers clinical research important, but they're not fans of the people behind it.
|
July 1, 2008
By:Kenneth A. Getz
Today's problem-plagued feasibility assessment process is in need of repair.
|
May 1, 2008
By:Kenneth A. Getz
More complex and demanding protocols are hurting clinical trial performance and success.
|
| 
